MENLO PARK, Calif., June 19, 2012 /PRNewswire/ -- Auxogyn, Inc., a company at the forefront of reproductive health innovation, today announced the commencement of a groundbreaking research study with Reproductive Medicine Associates of New Jersey (RMANJ), an internationally-renowned fertility clinic that has pioneered and successfully implemented cutting-edge clinical advancements to more accurately detect healthy embryos for patients undergoing in vitro fertilization (IVF).
"Auxogyn is committed to funding and conducting rigorous scientific research to continually improve outcomes for IVF patients," said Lissa Goldenstein, president and chief executive officer of Auxogyn. "We are pleased to partner with RMANJ and believe this study may expand our understanding of embryo development dramatically, potentially leading to further improvement in our ability to detect healthy embryos during assisted reproduction procedures."
Patients enrolled in the study will be those who have determined, after consultation with their physician, to undergo pre-implantation genetic diagnosis using Comprehensive Chromosome Screening (CCS), a new rapid-method 24-chromosome screening technique first implemented at RMANJ. During the study, all embryos will be monitored using the Eeva™ (Early Embryo Viability Assessment) Test, a non-invasive test developed by Auxogyn to record and quantitatively analyze embryo development against scientifically- and clinically-validated cell-division time periods.
"Our objectives at RMANJ are two-fold: to increase the healthy live birth rate for those undergoing assisted reproductive procedures, and to decrease the multiple embryo transfer rate, thereby reducing multiple pregnancies," commented Richard T. Scott, Jr., M.D., F.A.C.O.G., H.C.L.D., founding partner of RMANJ. "Through this collaborative research study with Auxogyn, we will explore new, previously unidentified factors that cause one euploid embryo to implant where another seemingly healthy embryo does not. These discoveries could directly impact clinical practice in the future, moving us closer to the ultimate goal of the IVF field – one embryo, one healthy baby."
About Reproductive Medicine Associates of New Jersey
Reproductive Medicine Associates of New Jersey have pioneered and successfully implemented a cutting-edge technology, known as Comprehensive Chromosome Screening (CCS) to more accurately detect healthy embryos that will lead to successful pregnancies and ultimately healthy babies. Other centers have attempted similar testing methods, but RMANJ is the only fertility center in the world to have developed a system of unprecedented accuracy, fully validated through years of rigorous clinical research. RMANJ's Comprehensive Chromosome Screening offers advanced embryo selection with extreme accuracy by detecting and avoiding use of embryos with chromosomal abnormalities prior to transfer and pregnancy.
The fertility experts at RMANJ have among the highest IVF success rates in the country. Since 1999, they have helped bring more than 20,000 babies to loving families. In addition to serving as the Division of Reproductive Endocrinology at Robert Wood Johnson University Medical School in New Brunswick, NJ, the practice has six locations in New Jersey. For more information please call RMANJ at 973-656-2089, or visit www.rmanj.com.
Auxogyn, Inc. is focused on advancing the field of reproductive health through its uniquely-combined knowledge of early human developmental biology, advanced computer vision technology and best clinical practices. The company's first product, the Eeva™ Test, is designed to provide quantitative information regarding embryo development to assist IVF clinicians in optimizing the treatment path for their patients undergoing IVF procedures. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For more information regarding Auxogyn please visit www.auxogyn.com.
|SOURCE Auxogyn, Inc.|
Copyright©2012 PR Newswire.
All rights reserved